A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer

计划入组 17 人 · 首次发布于 2024 年 7 月 24 日

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

计划入组 82 人 · 首次发布于 2022 年 6 月 10 日

Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer

计划入组 6 人 · 首次发布于 2023 年 10 月 30 日

177Lu-rhPSMA-10.1

255 Ac-rhPSMA-10.1

225 Ac-rhPSMA-10.1

Laureate Institute for Brain Research

United States

Aveta Biomics, Inc.

United States

Selcuk University

Turkey

Blue Earth Therapeutics' rhPSMA-10.1 Shows Promise in Phase 1 Trial for Prostate Cancer

Blue Earth Therapeutics Secures $76.5M to Advance PSMA-Targeted Radioligand Therapies

Blue Earth Therapeutics Doses First Patient in Phase 1 Trial of Alpha-Emitting PSMA Radiopharmaceutical for mCRPC